Sanofi has announced positive interim results from its early-stage study for the mRNA-based Covid-19 vaccine candidate it is developing with Translate Bio, a boost for the French drug company after delays with its other shot.
Sanofi said initial Phase I/II data showed neutralising antibody seroconversion in 91 per cent to 100pc of study participants, two weeks after a second injection, across all three dosages tested.
"These results will clearly help inform the path forward for our mRNA development programmes," said Jean-Francois Toussaint, global head of research and development at Sanofi Pasteur.
Read the full Reuters story here.
